US 12,476,009 B2
Immune age and use thereof
Shai S. Shen-Orr, Haifa (IL); Yishai Menachem Pickman, Lod (IL); and Ayelet Alpert, Haifa (IL)
Assigned to TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED, Haifa (IL)
Appl. No. 17/053,785
Filed by TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED, Haifa (IL)
PCT Filed May 7, 2019, PCT No. PCT/IL2019/050523
§ 371(c)(1), (2) Date Nov. 8, 2020,
PCT Pub. No. WO2019/215740, PCT Pub. Date Nov. 14, 2019.
Claims priority of provisional application 62/667,698, filed on May 7, 2018.
Prior Publication US 2021/0287807 A1, Sep. 16, 2021
Int. Cl. G16H 50/30 (2018.01); G01N 33/68 (2006.01); G16B 50/30 (2019.01); G16H 10/60 (2018.01)
CPC G16H 50/30 (2018.01) [G01N 33/6803 (2013.01); G16B 50/30 (2019.02); G16H 10/60 (2018.01)] 11 Claims
 
1. A method of diagnosing and treating an increased risk of cardiovascular disease of a subject, comprising:
(a) measuring relative abundance of at least 3 immune cell populations in a blood sample from said subject;
(b) determining an immunological age of said subject by at least one of:
(i) comparing said measurement of relative abundance of immune cell populations to a dataset of measurements of immune cell population relative abundance in subjects with predetermined immunological ages, wherein said comparing comprises employing a distance metric with respect to immune cell population abundance in said sample and samples of said dataset or selecting from said dataset individuals with a smallest distance with respect to relative abundance of said at least 3 immune cell populations and averaging an immunological age of said selected individuals; and
(ii) combining said measurement of relative abundances with data of measurements of relative abundance from at least 19 other subjects to produce a database, calculating from said database a trajectory for all at least 20 subjects based on said measurements of relative abundance, wherein said calculating a trajectory comprises applying a diffusion-pseudotime algorithm to said population relative abundancies;
(c) diagnosing said subject whose immunological age is greater than said subject's chronological age with an increased risk of cardiovascular disease or diagnosing said subject whose immunological age is greater than an immunological age of at least one other subject of the same chronological age with an increased relative risk of cardiovascular disease; and
(d) administering to said subject diagnosed with increased risk of cardiovascular disease or relative increased risk of cardiovascular disease a cardiovascular medication selected from: a statin, aspirin, an anticoagulant, an antiplatelet agent, an angiotensin receptor blocker, a beta blocker, a calcium channel blocker, a diuretic and a vasodilator;
thereby diagnosing and treating an increased risk of cardiovascular disease in a subject.